

STATUTORY INSTRUMENTS

**2015 No. 895**

**The Nicotine Inhaling Products (Age of Sale  
and Proxy Purchasing) Regulations 2015**

**Exception for medicines indicated for the treatment of persons aged under 18**

- 5.—(1) This regulation applies to the sale of a nicotine inhaling product which—
- (a) is an authorised medicinal product; and
  - (b) is indicated for the treatment of persons of the age of the person to whom the product is sold.
- (2) For the purposes of this regulation—
- (a) a product is indicated for the treatment of persons of a particular age if it is described as such in the summary of the product characteristics for the product in accordance with paragraph 27 of Schedule 8 to the Human Medicines Regulations 2012 (summary of the product characteristics) <sup>F1</sup> ...;
  - <sup>F2</sup>(b) .....
  - (c) a medicinal product is “authorised” if one of the following is in force for the product—
    - (i) a [<sup>F3</sup>UK] marketing authorisation; or
    - (ii) a parallel import licence.

**Textual Amendments**

- F1** Words in reg. 5(2)(a) omitted (31.12.2020) by virtue of [The Tobacco Products and Nicotine Inhaling Products \(Amendment etc.\) \(EU Exit\) Regulations 2019 \(S.I. 2019/41\)](#), regs. 1, **5(2)(a)**; 2020 c. 1, Sch. 5 para. 1(1)
- F2** Reg. 5(2)(b) omitted (31.12.2020) by virtue of [The Tobacco Products and Nicotine Inhaling Products \(Amendment etc.\) \(EU Exit\) Regulations 2019 \(S.I. 2019/41\)](#), regs. 1, **5(2)(b)**; 2020 c. 1, Sch. 5 para. 1(1)
- F3** Word in reg. 5(2)(c)(i) inserted (31.12.2020) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2019 \(S.I. 2019/775\)](#), reg. 1, **Sch. 8 para. 13(3)**; 2020 c. 1, Sch. 5 para. 1(1)

**Changes to legislation:**

There are currently no known outstanding effects for the The Nicotine Inhaling Products (Age of Sale and Proxy Purchasing) Regulations 2015, Section 5.